Targets › Ion channels
134 programs from 122 companies in 489 trials: 169 Phase 4, 143 Phase 2, 106 Phase 3, 71 Phase 1; Neurology, Cardiovascular, Other; next expected readout Nov 2026.
Open in Phaseline: the race on Ion channels, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | BCG Solution Glucagon-like peptide 1 receptor agonist | GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274 | Phase 4 | Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss … | Nov 2026 |
| Vanderbilt University Medical Center | [18F]MH.MZ Bacterial penicillin-binding protein inhibitor | HTR2A, UNKNOWN, BDKRB2, Ion channels | Phase 4 | Neurodegenerative Diseases; Osteoarthritis, Knee; Pain; Intradialytic Hypotension … | Nov 2026 |
| Jiangsu HengRui Medicine | Bupivacaine Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 4 | Local Analgesia Via Infiltration; Local Analgesia Via Nerve Block; Robotic Lung Surgery; Low Back Pain … | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Fayoum University Hospital | Lidocaine Hydrochloride Sodium channel alpha subunit blocker | Ion channels | Phase 4 | CAD | Nov 2026 |
| Retina Research Institute, LLC | Chloroprocaine Sodium channel alpha subunit blocker | Ion channels | Phase 4 | No Condition | Dec 2026 |
| Vertex Pharmaceuticals | Suzetrigine (SUZ, VX-548) Nav1.9 sodium channel inhibitor | Ion channels | Phase 4 | Pain; Diabetic Peripheral Neuropathic Pain; Opioid Consumption, Postoperative; Bariatric Surgery … | Jan 2027 |
| Viatris | Gabapentin Voltage-gated calcium channel modulator | Ion channels, CACNB4, CACNB2, CACNB1, CACNB3 | Phase 4 | Healthy; Tonsillitis; Dental Pain and Sensation Disorder; Pain, Postoperative … | Jan 2027 |
| Duke University | Mepivacaine Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Tourniquet Hypertension | Feb 2027 |
| All India Institute of Medical Sciences, Jodhpur | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 4 | Seizures | Mar 2027 |
| Bangladesh Medical University | Mirogabalin Voltage-gated calcium channel alpha2/delta subunit 1 modulator; Voltage-gated calcium channel alpha2/delta subunit 2 modulator | Ion channels | Phase 4 | Diabetic Peripheral Neuropathic Pain (DPNP) | Mar 2027 |
| All India Institute of Medical Sciences, Jodhpur | Phenytoin Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Seizures | Mar 2027 |
| Morten Steen Kvistholm Jensen | Verapamil Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Non-obstructive Hypertrophic Cardiomyopathy | Apr 2027 |
| Wake Forest University Health Sciences | lacosamide Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Traumatic Brain Injury | Apr 2027 |
| Brigham and Women's Hospital | Bupivacaine Hydrochloride Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 4 | Labor Pain | Jun 2027 |
| Anne E. Zepeski | diltiazem Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Supraventricular Tachycardia (SVT) | Jul 2027 |
| University of California, Los Angeles | Nifedipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Postpartum Hypertension (PPHT) | Jul 2027 |
| Affiliated Hospital of Nantong University | Zonisamide Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Epilepsies, Partial | Jul 2027 |
| Duke University | Chloroprocaine Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Knee Stiffness After Total Knee Arthroplasty | Aug 2027 |
| Guangdong Provincial People's Hospital | Crisugabalin Calcium channel alpha-2-delta subunit ligand | Ion channels | Phase 4 | PARKINSON DISEASE (Disorder) | Aug 2027 |
| Kumamoto University | Nicorandil ATP-sensitive potassium channel opener | Ion channels | Phase 4 | Coronary Artery Disease | Aug 2027 |
| Centre Hospitalier Universitaire de Nice | Verapamil Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Cluster Headache | Sep 2027 |
| University Hospital Dubrava | levobupivacaine Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 4 | Inguinal Hernia; Breast Tumors | Sep 2027 |
| Chinese University of Hong Kong | Levobupivacaine Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 4 | Musculoskeletal Diseases or Conditions | Sep 2027 |
| Aarhus University Hospital | Nicardipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Intracerebral Haemorrhage | Sep 2027 |
| University Hospital Bispebjerg and Frederiksberg | Lamotrigine Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Bipolar II Disorder | Dec 2027 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Amiodarone Hydrochloride HERG blocker | Ion channels | Phase 4 | Persistent Atrial Fibrillation | Dec 2027 |
| Leiden University Medical Center | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 4 | Glioma | Jan 2028 |
| Algemeen Ziekenhuis Maria Middelares | Levobupivacaine Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 4 | Analgesic Effect | Feb 2028 |
| Nebraska Methodist Health System | Nifedipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Postpartum Preeclampsia; Hypertension in Pregnancy | Jul 2028 |
| Shenzhen Ausa Pharmed | Amlodipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Hypertension; Atrial Fibrillation; Diabetes Mellitus, Type 2; Stroke … | Jun 2029 |
| Universitaire Ziekenhuizen KU Leuven | flecainide Sodium channel protein type V alpha subunit blocker | Ion channels | Phase 4 | Atrial Fibrillation (AF) | Dec 2029 |
| Stanford University | Amiodarone HERG blocker | Ion channels | Phase 4 | Postoperative Atrial Fibrillation | Dec 2030 |
| Yan Li | Amlodipine besylate Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Hypertension | – |
| University of Illinois Chicago | Flecainide Sodium channel protein type V alpha subunit blocker | Ion channels | Phase 4 | Atrial Fibrillation | – |
| University of Texas at Austin | Gabapentin Enacarbil Voltage-gated calcium channel modulator | Ion channels, CACNB4, CACNB2, CACNB1, CACNB3 | Phase 4 | Alzheimer Disease | – |
| Jinnah Postgraduate Medical Centre | Oxcarbazepine Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Trigeminal Neuralgia | – |
| University of South Florida | Phenazopyridine Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Pain After Urodynamic Testing | – |
| Louisiana State University Health Sciences Center in New Orleans | Proparacaine Sodium channel alpha subunit blocker | Ion channels | Phase 4 | Epiphora | – |
| University of Illinois Chicago | Sotalol Beta-1 adrenergic receptor antagonist; HERG blocker; Beta-2 adrenergic receptor antagonist | ADRB1, Ion channels, ADRB2 | Phase 4 | Atrial Fibrillation | – |
| Assiut University | Bupivacaine Hydrochloride Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 3 | Cleft Palate | Nov 2026 |
| Assistance Publique - Hôpitaux de Paris | Nifedipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 3 | Preterm Premature Rupture of Membrane | Nov 2026 |
| Industrial Farmacéutica Cantabria | Minoxidil Sulfonylurea receptor 2, Kir6.2 opener | Ion channels, ABCC9 | Phase 3 | Androgenetic Alopecia; Central Centrifugal Cicatricial Alopecia (CCCA); Survivors of Childhood Cancer; Breast Reconstruction | Nov 2026 |
| Xenon Pharmaceuticals | Azetukalner hERG potassium channel blocker | Ion channels | Phase 3 | Major Depressive Disorder; Bipolar Disorder; Bipolar Depression | Dec 2026 |
| Radboud University Medical Center | Diltiazem Voltage-gated L-type calcium channel blocker | Ion channels | Phase 3 | Microvascular Angina | Dec 2026 |
| Praxis Precision Medicines | elsunersen antisense oligonucleotide targeting SCN2A | Ion channels | Phase 3 | Epileptic Encephalopathy | Dec 2026 |
| Tata Memorial Hospital | 0.5% lignocaine 60mM Voltage-gated sodium channel blocker | Ion channels | Phase 3 | Operable Breast Cancer | Dec 2026 |
| Versailles Hospital | Amiodarone HERG blocker | Ion channels | Phase 3 | Ventricular Arrhythmias and Cardiac Arrest | Jan 2027 |
| Jilin Heart Hospital | Amiodarone HERG blocker | Ion channels | Phase 3 | Atrial Fibrillation (AF) | Jan 2027 |
| University of Sao Paulo | Lacosamide Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Bipolar Affective Disorder | Jan 2027 |
| Beijing Tiantan Hospital | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Postoperative Seizures After Brain Tumor Surgery | Jan 2027 |
| Lupin | Mexiletine Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Myotonia; Myotonic Dystrophy; Spinal and Bulbar Muscular Atrophy | Jan 2027 |
| University of California, San Francisco | Ropivacaine Hydrochloride Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Pregnancy; Adolescent Idiopathic Scoliosis (AIS) | Jan 2027 |
| Ono Pharmaceutical | ONO-2017 Sodium channel modulator; GABA-A receptor positive allosteric modulator | Ion channels, GABRA1 | Phase 3 | Epilepsy, Generalized | Jan 2027 |
| Tanta University | Nicorandil 5 MG Oral Tablet Potassium channel activator with anti-inflammatory properties | Ion channels | Phase 3 | Rhumatoid Arthisis | Mar 2027 |
| Stoke Therapeutics | zorevunersen antisense oligonucleotide targeting SCN1A | Ion channels | Phase 3 | Dravet Syndrome | Mar 2027 |
| Newron Pharmaceuticals | Evenamide Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Treatment-resistant Schizophrenia | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | Amiodarone HERG blocker | Ion channels | Phase 3 | Thoracic Surgery | Apr 2027 |
| Xenon Pharmaceuticals | XEN1101 Kv7 channel opener | Ion channels | Phase 3 | Primary Generalized Tonic-Clonic Seizures; Focal Onset Seizures; Focal Epilepsy | Apr 2027 |
| Milestone Pharmaceuticals Inc. | Etripamil NS L-type calcium channel blocker | Ion channels | Phase 3 | Atrial Fibrillation; Paroxysmal Supraventricular Tachycardia | Jun 2027 |
| Brainfarma Industria Química e Farmacêutica S/A | Pregabalin Voltage-gated calcium channel modulator | Ion channels, CACNB4, CACNB2, CACNB1, CACNB3 | Phase 3 | Diabetic Neuropathy; Shoulder Arthropathy; Pregabalin; Diabetic Pruritus … | Jun 2027 |
| LXO Ireland | Cocaine Sodium channel alpha subunit blocker | Ion channels | Phase 3 | ENT Disorder | Dec 2027 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Down Syndrome | Dec 2027 |
| Zhejiang Sunshine Mandi Pharmaceutical | Minoxidil Sulfonylurea receptor 2, Kir6.2 opener | Ion channels, ABCC9 | Phase 3 | Androgenetic Alopecia | Dec 2027 |
| Loma Linda University | Nifedipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 3 | Postpartum Complication | Dec 2027 |
| Oregon Health and Science University | Amiodarone Hydrochloride HERG blocker | Ion channels | Phase 3 | Cardiac Arrest | Dec 2027 |
| Nantes University Hospital | Lidocaine hydrochloride Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Vaso-Occlusive Pain Episode in Sickle Cell Disease | Aug 2028 |
| Oslo University Hospital | Flecainide Sodium channel protein type V alpha subunit blocker | Ion channels | Phase 3 | Mitral Valve Prolapse | Aug 2028 |
| Waad Alkathiri | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Epilepsy | Dec 2028 |
| Shanghai East Hospital | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Suspected Stroke | Dec 2028 |
| Samsung Medical Center | Zastaprazan citrate Potassium competitive acid blocker (P-CAB) | Ion channels | Phase 3 | Acute Myocardial Infarction (AMI) | Dec 2029 |
| Tanta University | ethosuximide T-type calcium channel blocker | Ion channels | Phase 3 | IBS - Irritable Bowel Syndrome | Dec 2030 |
| Population Health Research Institute | Amiodarone Hydrochloride HERG blocker | Ion channels | Phase 3 | Atrial Fibrillation New Onset | Dec 2030 |
| Tata Memorial Centre | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Seizures | Jun 2031 |
| Qassim Health Cluster | Articaine Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Dental Caries in Children | – |
| Soleno Therapeutics | Diazoxide Potassium channel, inwardly rectifying, subfamily J, member 11 opener; Potassium channel, inwardly rectifying, subfamily J, member 8 opener | Ion channels | Phase 3 | Prader-Willi Syndrome; Diabetes Mellitus; Hyperinsulinemia | – |
| Hippocration General Hospital | Flecainide Sodium channel protein type V alpha subunit blocker | Ion channels | Phase 3 | Atrial Fibrillation Paroxysmal | – |
| Assistance Publique - Hôpitaux de Paris | Flecainide Sodium channel protein type V alpha subunit blocker | Ion channels | Phase 3 | Patent Foramen Ovale | – |
| Grace Therapeutics | GTX-104 Nimodipine IV infusion - dihydropyridine calcium channel blocker | Ion channels | Phase 3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | – |
| AbbVie | Lidocaine Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Mid Face Volume Deficit; Blood Gas Analysis; Hemiplegia; Rib Fractures … | – |
| Medical College of Wisconsin | Nifedipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 3 | Preeclampsia; Hypertensive Disorder of Pregnancy | – |
| TLC Biopharmaceuticals | Ropivacaine (TLC590) Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Postoperative Pain; Postsurgical Pain Management; End Stage Renal Disease (ESRD); Hepatic Resection … | – |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Crisugabalin Voltage-gated calcium channel alpha-2-delta subunit ligand | Ion channels | Phase 2 | Neuropathic Pain | Nov 2026 |
| Memorial Sloan Kettering Cancer Center | Glipizide Sulfonylurea receptor 1, Kir6.2 blocker | Ion channels, ABCC8 | Phase 2 | Pancreatic Cancer | Dec 2026 |
| Actio Biosciences | ABS-1230 KCNT1 inhibitor | Ion channels | Phase 2 | KCNT1-Related Epilepsy | Dec 2026 |
| Biohaven Therapeutics | BHV-7000 ATP-sensitive potassium channel opener | Ion channels | Phase 2 | Focal Epilepsy; Familial Erythromelalgia | Dec 2026 |
| Johns Hopkins University | Levetiracetam (AGB101) Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Parkinson Disease Psychosis; Hippocampal Overactivity | Dec 2026 |
| National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Refralon® I_K,ACh channel antagonist; I_to current inhibitor; anti-arrhythmic | Ion channels | Phase 2 | Atrial Fibrillation | Dec 2026 |
| Daniel Raper, MBBS | Lidocaine hydrochloride Sodium channel alpha subunit blocker | Ion channels | Phase 2 | Headaches Associated With Subarachnoid Hemorrhage (SAH) | Jan 2027 |
| Anhui Medical University | Crisugabalin alpha-2-delta ligand | Ion channels | Phase 2 | Generalized Anxiety Disorder | Jan 2027 |
| Ain Shams University | Verapamil Voltage-gated L-type calcium channel blocker | Ion channels | Phase 2 | Type 1 Diabetes Mellitus | Feb 2027 |
| University of Alberta | Ranolazine Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 2 | Pulmonary Hypertension | Mar 2027 |
| Tavo Biotherapeutics | TB0001 ophthalmic solution 0.9% GABA analog; voltage-gated calcium channel modulator | Ion channels | Phase 2 | Primary Open - Angle Glaucoma (POAG) | Jun 2027 |
| VM Therapeutics | VMD-3866 Gel T-type calcium channel inhibitor | Ion channels | Phase 2 | Chemotherapy-induced Peripheral Neuropathy | Jun 2027 |
| University of California, San Diego | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Neonatal Seizure | Jul 2027 |
| John Elfar | Dalfampridine Voltage-gated potassium channel blocker | Ion channels | Phase 2 | Nerve Injury; Wounds; Burns | Jul 2027 |
| Ain Shams University | Nicorandil ATP-sensitive potassium channel opener with nitrate-like vasodilatory properties | Ion channels | Phase 2 | Rheumatoid Arthritis (RA) | Jul 2027 |
| University of California, Irvine | Riluzole Sodium channel alpha subunit blocker | Ion channels | Phase 2 | Breast Cancer | Jul 2027 |
| OHSU Knight Cancer Institute | Amiodarone Hydrochloride HERG blocker | Ion channels | Phase 2 | Atrial Fibrillation | Aug 2027 |
| Washington State University | Zonisamide Sodium channel alpha subunit blocker | Ion channels | Phase 2 | Alcohol Use Disorder (AUD) | Aug 2027 |
| HB BioTech | HB-1 Angiotensin II receptor antagonist (telmisartan) and calcium channel blocker (verapamil) | AGTR1, Ion channels | Phase 2 | PTSD | Sep 2027 |
| Sunnybrook Health Sciences Centre | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Hippocampal Hyperactivation | Dec 2027 |
| University Hospital, Basel, Switzerland | Nicardipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 2 | Hepato Cellular Carcinoma (HCC) | Jun 2028 |
| Swathy Chandrashekhar, MBBS | Ranolazine Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 2 | Amyotrophic Lateral Sclerosis | Jul 2028 |
| University of Florida | Verapamil Voltage-gated L-type calcium channel blocker | Ion channels | Phase 2 | Type 1 Diabetes | Nov 2028 |
| Ayal A. Aizer, MD | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Seizures | Feb 2029 |
| Biossil | Senicapoc (SIL-8301) Intermediate conductance calcium-activated potassium channel protein 4 blocker | Ion channels | Phase 2 | Sickle Cell Disease; Mild Cognitive Impairment; Pulmonary Fibrosis, Interstitial Lung Disease | Oct 2029 |
| Sohag University | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Generalized Convulsive Status Epilepticus | – |
| Sahiwal medical college sahiwal | Lidocaine Hydrochloride Sodium channel alpha subunit blocker | Ion channels | Phase 2 | Hemodynamics Instability | – |
| PAEC General Hospital, Islamabad | Lidocaine Hydrochloride Sodium channel alpha subunit blocker | Ion channels | Phase 2 | Postoperative Sore Throat, Cough, Hoarseness | – |
| Ohio State University Comprehensive Cancer Center | Lidocaine Hydrochloride Sodium channel alpha subunit blocker | Ion channels | Phase 2 | Cutaneous Melanoma | – |
| Federico II University | Ranolazine Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 2 | STEMI (ST Elevation MI) | – |
| University of Utah | Riluzole Sodium channel alpha subunit blocker | Ion channels | Phase 2 | Atrial Fibrillation Paroxysmal | – |
| S. Andrea Hospital | Riluzole Sodium channel alpha subunit blocker | Ion channels | Phase 2 | SCA7 | – |
| Jaeb Center for Health Research | Tonabersat Selective T-type calcium channel inhibitor | Ion channels | Phase 2 | Diabetic Macular Edema | – |
| Hangzhou Yirui Pharmaceutical Technology | PA032 Kv1.3 potassium channel blocker | Ion channels | Phase 1 | Health Adult Subjects | Nov 2026 |
| Valenta Pharm JSC | Benoxinate Sodium channel alpha subunit blocker | Ion channels | Phase 1 | Pharyngitis | Dec 2026 |
| Global Neurosciences Institute | Verapamil Voltage-gated L-type calcium channel blocker | Ion channels | Phase 1 | Ischemic Stroke | Dec 2026 |
| University of Alabama at Birmingham | Nifedipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 1 | Hypertension in Pregnancy | Dec 2026 |
| Pacira Pharmaceuticals | Bupivacaine Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 1 | Postoperative Pain | Jan 2027 |
| Indiana University | Lacosamide Sodium channel alpha subunit blocker | Ion channels | Phase 1 | Chronic Pain | Mar 2027 |
| Francis Farhadi | Glyburide Sulfonylurea receptor 1, Kir6.2 blocker | Ion channels, ABCC8 | Phase 1 | Acute Spinal Cord Injury | May 2027 |
| Beijing Friendship Hospital | Crisugabalin Calcium channel modulator (alpha-2-delta ligand) | Ion channels | Phase 1 | Restless Leg Syndrome (RLS) | Jun 2027 |
| Sangamo Therapeutics | ST-503 Gene therapy delivering modified gene to repress Nav1.7 (SCN9A) tissue-related pain signal | Ion channels | Phase 1 | Chronic Neuropathic Pain | Jul 2027 |
| Hospital Universitario La Fe | Opioid-Free Anesthesia (OFA) Multimodal non-opioid protocol: alpha-2 agonist (Dexmedetomidine), sodium channel blocker | ADRA2A, Ion channels, NMDA | Phase 1 | Pain Management | Jul 2027 |
| National Cancer Institute (NCI) | Riluzole Sodium channel alpha subunit blocker | Ion channels | Phase 1 | Advanced Malignant Solid Neoplasm | Sep 2027 |
| Praxis Precision Medicines | PRAX-222 Selective sodium channel modulator targeting SCN2A mutations | Ion channels | Phase 1 | SCN2A-DEE | Feb 2028 |
| Institut de Recherches Internationales Servier | S230815 KCNT1 activator | Ion channels | Phase 1 | Epileptic Encephalopathy | Apr 2028 |
| Mayo Clinic | Diltiazem Hydrochloride Voltage-gated L-type calcium channel blocker | Ion channels | Phase 1 | Malignant Digestive System Neoplasm | Apr 2028 |
| Encoded Therapeutics | ETX101 AAV9-delivered gene therapy encoding engineered transcription factor (eTFSCN1A) to increas | Ion channels | Phase 1 | Dravet Syndrome | Jun 2028 |
| Johnny Ludvigsson | Verapamil Voltage-gated L-type calcium channel blocker | Ion channels | Phase 1 | Type 1 Diabetes | Dec 2029 |
| City of Hope Medical Center | Verapamil Voltage-gated L-type calcium channel blocker | Ion channels | Phase 1 | Type 1 Diabetes | Apr 2030 |
| Helios Cardio | Amiodarone-Infused CardiaMend patches Topical amiodarone delivery to epicardial atrial surface | Ion channels | Phase 1 | Atrial Fibrillation, Postoperative | – |
| University of California, San Diego | nL-SCN2A-002 antisense oligonucleotide targeting SCN2A | Ion channels | Phase 1 | Genetic Disease | – |
Pain, Postoperative (9) Postoperative Pain (8) Atrial Fibrillation (7) Dravet Syndrome (5) Breast Cancer (5) Pain Management (5) Type 1 Diabetes (4) Rib Fractures (4) Post Operative Pain (4) Hip Disease (4) Labor Pain (4) Acute Pain (4)
small molecule (122), mixed (4), other (3), protein or peptide (2)
Xenon Pharmaceuticals (2) Duke University (2) University of California, San Diego (2) Assistance Publique - Hôpitaux de Paris (2) Memorial Sloan Kettering Cancer Center (2) Mayo Clinic (2) Praxis Precision Medicines (2) Ain Shams University (2) Tanta University (2) University of Illinois Chicago (2) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (2) All India Institute of Medical Sciences, Jodhpur (2) University Hospital Bispebjerg and Frederiksberg (1) University of Utah (1) Nebraska Methodist Health System (1) HB BioTech (1) Johnny Ludvigsson (1) Encoded Therapeutics (1) Samsung Medical Center (1) University of Florida (1)
SV2A (12) CACNB4 (4) CACNB2 (4) CACNB1 (4) CACNB3 (4) ABCC9 (2) ABCC8 (2) ADRA2A (2) HTR2A (2) OPRM1 (2) AGTR1 (1) NMDA (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.